2,4-二碘恶唑 | 1037597-73-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,4-二碘恶唑
• 英文名称: 2,4-diiodooxazole
• 英文别名: 2,4-diiodo-1,3-oxazole
• CAS: 1037597-73-1
• 化学式: C₃HI₂NO
• 分子量: 320.856
• InChiKey: VADMQUDKNXZWFT-UHFFFAOYSA-N

物化性质

• 熔点：
  98-103℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-碘丁烷 、 2,4-二碘恶唑 在 叔丁基锂 、 8-甲氧基-9-硼杂双环[3.3.1]壬烷 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三苯胂 、 caesium carbonate 作用下， 以 四氢呋喃 、 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.08h， 以76%的产率得到2-butyl-4-iodooxazole
  参考文献：
  名称：

  An efficient preparation of 2-alkyl-oxazoles from 2-iodooxazoles

  摘要：

  An efficient synthesis toward 2-alkyl substituted oxazoles has been achieved through Suzuki cross-coupling reaction. Treatment of various alkyl iodides with 9-MeO-BBN, followed by in situ palladium-catalyzed carbon-carbon formation with 2-iodooxazoles obtained the 2-alkyl substituted oxazoles in good to excellent yields. Regioselective C2-alkylation on 2,4-di-iodooxazole under the same reaction conditions was firstly disclosed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.05.088
• 作为产物：
  描述：

  恶唑 在 全氟碘代丁烷 、 sodium t-butanolate 作用下， 以75 %的产率得到2,4-二碘恶唑
  参考文献：
  名称：

  阴离子对全氟烷基碘化物的活化：将卤素键活化的范围扩展到 C(sp3)–H 酰胺化、C(sp2)–H 碘化和全氟烷基化反应

  摘要：

  在没有昂贵的光催化剂或过渡金属催化剂的情况下，通过t BuONa 或 KOH对全氟烷基碘进行简单、高效和方便的活化，可以促进烷基醚和苄基烃、C-H 的通用 α-sp 3 C-H 酰胺化反应杂芳基化合物的碘化，以及富电子π键的全氟烷基化。机理研究表明，这些新方案基于全氟烷基碘与t BuONa 或 KOH 之间的卤素键相互作用，可促进全氟烷基碘在温和条件下均裂。

  DOI：

  10.1039/d2sc06145g

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2013062945A1

  公开（公告）日：2013-05-02

  The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b - and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的杂芳基衍生物。具体而言，本发明涉及根据公式Q的化合物：其中D、L、M、W、X、Y和Z在此定义。本发明的化合物是DNA甲基转移酶（DNMT）活性的抑制剂，包括DNMT1、DNMT3a或DNMT3b，并且可用于治疗癌症和过度增殖性疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制DNMT活性和治疗相关疾病的方法。
• [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DU RÉCEPTEUR DU CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2015161014A1

  公开（公告）日：2015-10-22

  The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及杂环化合物，其是CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的这类疾病中使用这些化合物和组合物。
• [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2014120346A1

  公开（公告）日：2014-08-07

  The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

  本发明提供了一种式（I）的化合物（结构表示），其中R1为H或C1-6烷基，R2为H或C1-6烷基或CH20H，R3为H或C1-6烷基，R4为H或C1-6烷基，但当R1、R2和R3为H时，R4为C1-6烷基，当R1、R2和R4为H时，R3为C1-6烷基，当R1、R3和R4为H时，R2为C1-6烷基或-CH20H，当R2、R3和R4为H时，R1为C1-6烷基；A为1）具有1-3个异原子（N、S和O中独立选择）的9-10成员双环杂环，该9-10成员双环杂环未取代或取代为R5、未取代或取代为R6、未取代或取代为NH2；或2）未取代或取代为R5、未取代或取代为R6、未取代或取代为-CH2NH2的6-9成员单环或双环碳环系统；B为1）具有1或2个异原子（N、S或O中独立选择）的5-或6成员单环杂环，未取代或在碳或氮原子上取代为R7、未取代或在碳或氮原子上取代为R8、未取代或在碳或氮原子上取代为R9；或2）具有1、2或3个氮原子的8-或9成员融合双环杂环，在碳或氮原子上未取代或取代为R7，并在碳或氮原子上未取代或取代为R8；以及包括一种或多种这些化合物的制药组合物，以及使用这些化合物用于治疗或预防血栓形成的方法。
• Catalyst-Controlled Regioselective Suzuki Couplings at Both Positions of Dihaloimidazoles, Dihalooxazoles, and Dihalothiazoles
  作者：Neil A. Strotman、Harry R. Chobanian、Jiafang He、Yan Guo、Peter G. Dormer、Christina M. Jones、Janelle E. Steves

  DOI：10.1021/jo100148x

  日期：2010.3.5

  dihaloazoles can be monoarylated at a single C−X bond with high selectivity via Suzuki coupling. By changing the palladium catalyst employed, the selectivity can be switched for some dihaloazoles, allowing for Suzuki coupling at the other, traditionally less reactive C−X bond. These conditions are applicable to coupling of a wide variety of aryl-, heteroaryl-, cyclopropyl-, and vinylboronic acids with

  各种二卤代唑可以通过Suzuki偶联在单个C-X键上以高选择性单芳基化。通过改变所用的钯催化剂，可以切换一些二卤代唑的选择性，从而使Suzuki偶联在另一个传统上反应性较小的C-X键上。这些条件适用于以高选择性偶联各种芳基，杂芳基，环丙基和乙烯基硼酸，并能够以模块化的方式快速构建各种不同的二芳基唑阵列。
• CHEMICAL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20140296204A1

  公开（公告）日：2014-10-02

  The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代杂环基衍生物。具体而言，本发明涉及符合公式Q的化合物：其中D、L、M、W、X、Y和Z在此定义。本发明的化合物是DNA甲基转移酶（DNMT）活性的抑制剂，包括DNMT1、DNMT3a或DNMT3b，并且在癌症和高增殖性疾病的治疗中有用。因此，本发明进一步涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物抑制DNMT活性和治疗与之相关的疾病的方法。